Latest Patent Further Strengthens Intellectual Property Portfolio Covering Novel Platform for Precisely Controlling Regenerative Protein Expressions Including Stem Cell Homing and Differentiation Control
Technology Has Key Potential Applications in Regeneration of Failing Heart, Brain, Kidney, Liver, Pancreas, Lungs, Aorta, Vision and Hearing as well as Transcutaneous Uses for Accelerated Wound Healing, Skin, Hair and Penile Function Regeneration (ED)
Irvine, California, May 27th, 2020 – Leonhardt’s Launchpads, an innovation and startup launch accelerator focused on developing novel therapeutics that harness the body’s innate mechanisms to regenerate failing organs and to heal tissues, today announced the issuance of a new U.S. patent providing broad protection for the company’s first-of-its-kind combination bioelectrics and biologics technology platform, which has multiple potential therapeutic applications in organ regeneration and recovery.
“Previous stem cell therapies that delivered stem cells alone in a single application failed to regenerate organs fully. Electrical stimulation technologies to date have failed to zero in on and deliver the precise right bioelectric signaling sequences for controlling specific regenerative protein expressions when and where needed. This pioneering technology platform is the first to combine the powerful ability of bioelectric stimulation with repeat deliveries of not just stem cells but a whole host of support factors– similar to an egg yolk– designed to help cells survive, proliferate, engraft and differentiate with the intention of fully regenerating failing organs.” stated primary inventor, Executive Chairman and CEO Howard J. Leonhardt.
U.S. Patent 10,646,644 Issued May 12th, 2020 – https://patents.justia.com/patent/10646644 covers bioelectric stimulation controlled release of SDF1 and PDGF known stem cell homing and proliferation factors as well as use of a re-fillable micro infusion pump for slow infusion of a mixed composition of stem cells, exosomes, micro RNAs, nutrient hydrogel, growth factor cocktail, selected alkaloids and anti-inflammatory agents with the intention of regenerating organs and healing tissues. SDF1 and PDGF highlighted in these new patent claims also have strong capabilities in promoting arteriogenesis (mature blood vessel growth).
The Leonhardt team has separately filed or acquired patent claims for bioelectric controlled expression of follistatin, klotho, tropoelastin, VEGF, IGF1, CXCL5, HIF1a, EGF, HGF, OPG, RANKL and COL17A1 all known to have a role in organ healing https://patents.justia.com/patent/20180064935. Separately the Leonhardt’s Launchpads startup CancerCell has 9 issued U.S. patents https://cancercellinc.com/list-of-the-issued-cancer-patents/ for bioelectric treatment of cancer and dozens of additional cancer treatment related claims pending https://patents.justia.com/patent/20190030330. The team has filed patent clams on the combination of bioelectric stimulation and PRF https://patents.justia.com/patent/20200000709. Other important patent filings have been submitted on bioelectric inflammation management https://patents.justia.com/patent/20190022389 and blood pressure management https://patents.justia.com/patent/20190022396
The Leonhardt’s Launchpads technology platform is based on foundational scientific research that began in the late 1980’s working with Dr. Race Kao and Dr. George Magovern Sr. in Pittsburgh when they injected satellite cells (myoblasts or muscle stem cells) to repair damaged heart tissue in dogs and published the results in The Physiologist in 1989. In 1995 Howard Leonhardt filed his first patent for a stem cell and biologics delivery system for organ repair – ProCell https://patents.google.com/patent/US5693029A/en based on work that began in 1988. In 1998 the Leonhardt team began collaboration with Dr. Doris Taylor whom that year published a landmark paper in Nature Medicine https://www.nature.com/articles/nm0898-929 on repair of infarcted hearts with myoblast cells. Dr. Taylor currently still serves as co-chair of our Scientific Advisory Board today. In 1999 the Leonhardt team worked with Dr. Shinichi Kanno to publish in Circulation, the Journal of the American Heart Association, pioneering results with bioelectric stimulation driven VEGF protein expression for limb salvage via angiogenesis in animals https://www.ahajournals.org/doi/abs/10.1161/01.cir.99.20.2682\ and filed a patent application for the same within a year. Since then the Leonhardt team and Leonhardt’s Launchpads and its portfolio of startups has had issued, pending, optioned or licensed over 600 patent claims for organ regeneration and recovery. In 2001 Howard Leonhardt and Dr. Juan Chachques filed patents on bioelectric stimulation controlled myogenesis and dynamic cardiac support with an early less potent stem cell homing signal. That same year a Leonhardt led team working with Dr. Patrick Serruys completed the landmark first ever case of non-surgical cell based regeneration of a damaged human heart in The Netherlands. Howard Leonhardt began a collaboration at that time with Dr. Jorge Genovese co-inventor of this patent, and BioLeonhardt’s VP of Bioelectric Regeneration Research, that continues to this day. Over 200 dedicated talented people help Leonhardt’s Launchpads and its startups advance their developments almost every day – see Team https://leonhardtventures.com/team/ and Scientific Advisory Board –https://calxstars.com/scientific-advisory-board/.
About Leonhardt’s Launchpads:
Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc. in California, Leonhardt’s Launchpads Utah, Inc., Leonhardt’s Launchpads Australia PTY and Leonhardt’s Launchpads branches in Minneapolis, Pittsburgh and Brazil are the innovation and startup launch accelerator arms of Leonhardt Ventures (Leonhardt Vineyards LLC DBA Leonhardt Ventures). Leonhardt Ventures has been developing breakthrough medtech and biotech innovations since the 1980’s. In the 1980’s the team patented, developed and commercialized the PolyCath line of cardiovascular balloon catheters. In the 1990’s they developed and completed the first non-surgical repair of an aortic aneurysm (Melbourne, Australia 1995) and patented what is still today the leading endovascular stent graft for aortic aneurysm repair. In that time period they also patented one of the first percutaneous heart valve systems. Since 2000 the team has been focused almost exclusively on stem cell, biologics and bioelectric based organ regeneration and healing. In May of 2001 the team completed the landmark first ever non-surgical case of cell therapy for heart damage recovery. In 2008 the team began exploring if what they had learned from research in regenerating hearts could be translated to other organs. The organization now has 30 related startups and organ specific innovations in its 2020 portfolio class https://leonhardtventures.com/development-pipeline/ in these groups (1) Heart & Cardiovascular, (2) Brain, (3) Cosmetic & Reproductive Health, (4) Major Organ Regeneration and (5) Cancer. The accelerator business model is to accelerate each organ specific innovation through first in human studies and then secure a strategic partner to advance the product through commercialization.
Click on Leonhardt Ventures and Leonhardt’s Launchpads 2020 Annual Report for more information https://leonhardtventures.com/wp-content/uploads/2020/04/4_23_2020.pdf and our web site at www.leonhardtventures.com
See previous PDGF related press release – https://www.biospace.com/article/releases/-b-leonhardt-b-and-b-genovese-b-file-patent-for-bioelectric-controlled-expression-of-pdgf-a-powerful-organ-regeneration-cytokine-/
See previous KLOTHO anti-aging related press release – https://www.biospace.com/article/leonhardt-s-launchpads-announces-filing-of-patent-for-bioelectric-stimulation-controlled-klotho-expression-powerful-anti-aging-and-regeneration-promoting-protein-/
Contact See contact page on web site for contact information for all locations and phone numbers – https://leonhardtventures.com/contact/
Warning and Disclaimers: Product(s) are not yet proven safe or effective. Patents pending may not be issued. Patents licensed or optioned may not be maintained. Patents issued may be invalidated. Products are in early stage development. Forward looking statements may change without notice. As an investment these startups mentioned are in the highest risk category for total loss and only suitable for sophisticated experienced accredited investors. The company does not have on hand sufficient resources to bring these products through clinical studies and may not obtain these resources. The company is under staffed and under funded compared to most other participants in this space. Due to a small staff at the accelerator to maintain all web sites and other published materials they may not be fully up to date and there may be out date inaccurate information. If you have any questions on our products or our company please write us to ask.
Leonhardt’s Launchpads by Cal-X Stars,
18575 Jamboree Rd #6, Irvine, CA 92612
Leonhardt’s Launchpads Utah, Inc.
Research Lab @ 2500 S State St. #D249, Salt Lake City, UT 84115